Drug development for neglected ultra-rare diseases of no commercial interest: Challenges and opportunities
Related Experiment Video
Updated: Aug 4, 2026

ALS - Motor Neuron Disease: Mechanism and Development of New Therapies
Published on: July 29, 2007
Joseph A Katakowski1, Juan C López2
1RTW Foundation, 40 Tenth Avenue, Third Floor, New York, NY 10014, USA.
Abstract:
Ultra-rare diseases, particularly those that affect a few hundred patients worldwide, are of little commercial interest to the pharmaceutical industry. Patient-led organizations have made remarkable progress in funding the early-stage, academic development of therapies for such neglected ultra-rare conditions. But the long and difficult path to translate most academic proof-of-concept studies into approved medicines means that very few therapies ever reach patients. Here, we discuss some of the roadblocks to the development of therapeutics for conditions of limited commercial interest and propose ways to overcome these obstacles.
Related Concept Videos
Drug Discovery: Overview
Clinical Trials: Overview
Drug Regulation
Preclinical Development: Overview
Prescription, Nonprescription and Orphan Drugs
The misuse and addiction to prescription drugs is a growing problem that can affect people of all age groups, specifically teenagers. This can happen when prescription medications are used in ways not intended by the prescriber, such as taking someone else's prescription or using medication for...
Pharmacogenomics: Identification of New Drug Targets

